INTERWEST VENTURE MANAGEMENT CO - Q2 2018 holdings

$237 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 12 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 0.0% .

 Value Shares↓ Weighting
TSRO  TESARO INC$89,907,000
-22.2%
2,021,7380.0%37.98%
-22.0%
GKOS  GLAUKOS CORP$41,386,000
+31.8%
1,018,3620.0%17.48%
+32.2%
MGNX  MACROGENICS INC$22,185,000
-17.9%
1,074,3160.0%9.37%
-17.7%
EIGR  EIGER BIOPHARMACEUTICALS INC$19,515,000
+23.9%
1,599,5920.0%8.24%
+24.2%
HAIR  RESTORATION ROBOTICS INC$11,645,000
-44.3%
3,355,7860.0%4.92%
-44.2%
CDTX  CIDARA THERAPEUTICS INC$7,055,000
+30.0%
1,356,8130.0%2.98%
+30.4%
AGTC  APPLIED GENETIC TECHNOL CORP$5,387,000
-3.9%
1,455,9040.0%2.28%
-3.6%
OBLN  OBALON THERAPEUTICS INC$5,275,000
-37.3%
2,453,3380.0%2.23%
-37.2%
IVTY  INVUITY INC$4,213,000
+1.3%
1,080,2720.0%1.78%
+1.6%
KALV  KALVISTA PHARMACEUTICALS INC$2,679,000
-14.4%
329,9420.0%1.13%
-14.1%
XENE  XENON PHARMACEUTICALS INC$76,000
+230.4%
8,2930.0%0.03%
+220.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-07-05
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLAUKOS CORP28Q3 202333.0%
EIGER BIOPHARMACEUTICALS INC24Q3 202217.7%
APPLIED GENETIC TECHNOL CORP24Q3 20226.7%
XENON PHARMACEUTICALS INC20Q3 20210.6%
CIDARA THERAPEUTICS INC19Q2 20214.5%
THE REALREAL18Q3 202362.6%
KALVISTA PHARMACEUTICALS INC17Q4 202010.8%
DARE BIOSCIENCE INC16Q3 20230.3%
MACROGENICS INC14Q1 202019.2%
PMV PHARMACEUTICALS INC13Q3 202367.5%

View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.

Latest filings
TypeFiled
1442024-02-27
13F-HR2023-10-20
13F-HR2023-07-21
13F-HR2023-04-27
13F-HR2023-01-31
13F-HR2022-10-25
13F-HR2022-08-02
13F-HR2022-04-13
13F-HR2022-01-25
13F-HR2021-10-19

View INTERWEST VENTURE MANAGEMENT CO's complete filings history.

Compare quarters

Export INTERWEST VENTURE MANAGEMENT CO's holdings